OncoMatch/Clinical Trials/NCT07156253
Study of SYN818 With Olaparib for the Treatment of Locally Advanced or Metastatic Solid Tumors
Is NCT07156253 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies SYN818 and Olaparib will be administered for metastatic solid tumor.
Treatment: SYN818 and Olaparib will be administered — This interventional study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of SYN818 with Olaparib in adult patients with locally advanced or metastatic solid tumors
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Ovarian Cancer
Breast Carcinoma
Biomarker criteria
Required: BRCA1 mutation
Required: BRCA2 mutation
Disease stage
Required: Stage III, IV
Metastatic disease required
locally advanced or metastatic ... at least one measurable lesion according to RECIST v1.1
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: standard-of-care treatment
has exhausted all standard-of-care treatment options
Cannot have received: DNA Polymerase Theta (POLQ) inhibitor
Previous or current use of DNA Polymerase Theta (POLQ) inhibitors
Cannot have received: anti-cancer small molecule
Exception: within 5 half-lives (t1/2), or 2 weeks, whichever is shorter
Treatment with an anti-cancer small molecule within 5 half-lives (t1/2), or 2 weeks, whichever is shorter
Lab requirements
Blood counts
Adequate bone marrow function
Kidney function
No serious kidney diseases other than the primary disease; adequate organ function
Liver function
No serious liver diseases other than the primary disease; adequate organ function
Cardiac function
No serious cardiopulmonary diseases other than the primary disease
No serious hematological, cardiopulmonary, or liver or kidney diseases other than the primary disease; Adequate organ function and bone marrow function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify